View this email in your browser

REPRIEVE
Randomized Trial to Prevent Vascular Events in HIV

Trial Status
June 11, 2018

6721 participants are enrolled
18 participants enrolled last week
229 participants are in screening
117 sites are open for enrollment
14 sites enrolled at least 1 participant in the past week
21 sites screened at least 1 participant in the past week

Thank you for the excellent effort that all teams are putting forth to enroll participants in REPRIEVE.

Thank You to All Sites Enrolling Participants Week of June 4th, 2018!

Cincinnati CRS
Penn Therapeutics CRS
Barranco CRS
Joint Clinical Research Centre (JCRC)/Kampala CRS
Houston AIDS Research Team CRS
University of Rochester Adult HIV Therapeutic Network CRS
University of Cape Town Lung Institute
Thai Red Cross AIDS Research Center
UT Southwestern
Hamilton Health Sciences
Mt Sinai West CRS
School of Medicine, Federal University of Minas Gerais CRS
Instituto de Infectologia Emilio Ribas CRS
Tropical Medicine Foundation

Barbra Streisand Visits National Institutes of Health

Barbra Streisand Praises REPRIEVE During Speech at the National Institutes of Health

Taking Women's Health to Heart: An Afternoon with Barbra Streisand

Barbra Streisand recently presented the J. Edward Rall Cultural Lecture at the National Institutes of Health. She is a champion of gender equality and raising awareness about women's heart health. Streisand is also co-founder of the Women's Heart Alliance whose mission is to improve research, prevention and care to prevent women from dying of heart disease. During her speech, Streisand commended REPRIEVE investigators for recruiting a racially and ethnically diverse group of women and men in the trial so that analysis of sex-specific differences of immune activation and statin-induced effects on the immune system in relation to clinical cardiovascular disease events can be determined. She also praised the *Follow YOUR Heart* campaign that is working to break down barriers for women to become trial participants.

To know more about this enlightening event click here to watch the video, read the article in the Washington Post or read the Intramural Blog at NIH.

For Sites Participating in the Mechanistic Substudy of REPRIEVE (A5333s)

We have been informed that sites participating in both A5332 and A5333s should submit a Version 4.0, LOA #1 Protocol Signature Page (PSP) that references both studies. Click here to download a PSP that can be used, this PSP will also be posted on the PSWP.

If you have any questions, please email the A5333s Core Team at
actg.corea5333s@fstrf.org

A Reminder About New REPRIEVE Staff

If a new staff member is going to be a CRS Leader, CRS Coordinator, IoR, or REPRIEVE Pharmacist, approval by DAIDS OCSO is needed before these new staff begin their role for the REPRIEVE trial. You must contact your DAIDS OCSO Program Officer or email OCSOREPRIEVETeam@mail.nih.gov before making any such change.

Also click here to download a useful tool to orient new staff on REPRIEVE; this is also located in the Protocol Training folder on the PSWP.

It's the Season for AIDS Walk/Run Events!

Don't forget that many local AIDS service organizations hold AIDS Walk/Run events during the spring and summer. These events are an excellent opportunity to get the word out about REPRIEVE.

If you need REPRIEVE materials or REPRIEVE T-shirts for this type of community event, please contact Emma Kileel at the REPRIEVE Clinical Coordinating Center who can provide you such materials; and don't forget to send us any pictures of your REPRIEVE team at the event so we can share them in future newsletters!

Please forward this information to the relevant laboratory personnel at your site

LDMS Preloads & Quick Add Tips

LDMS Preloads (Windows) and Quick Add Templates (Web) allow laboratory staff to quickly and easily enter samples into LDMS by pre-populating the specimen entry screen with expected specimens.

Benefits include:

- Faster and more accurate data entry
- Reduced data queries
- Use of correct specimen codes
- Use of correct aliquot counts

Laboratories must follow the schedule and instruction in the LPC. Preloads and Quick Add are helpful data entry tools but they are not meant to replace protocol documents.

Click here to download a quick reference guide or reference the LDMS manual available on the LDMS website (www.ldms.org)

Ship Priority Overnight!

For sites using FedEx to ship specimens to BRI, ship PRIORITY OVERNIGHT this will ensure that your shipments arrive on time and during BRI's business hours.

Please Join the Next Monthly Site Call!

Tuesday, June 19th between 1:00 – 2:00 PM ET!

REPRIEVE (A5332): Are you up to date?

For A5332 please use:
Protocol Version 4.0 dated 03/28/2018
V4 LOA #1 dated 05/16/2018 (NEW!)
MOPS Version 4.0 dated 04/10/2018
A5332 LPC for ACTG Sites Version 4.0 dated 03/22/2018
A5332 LPC for Non-ACTG Sites Version 4.0 dated 03/22/2018
These documents are on the A5332 PSWP

Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?

For A5333s please use
Protocol Version 4.0 dated 03/28/2018
MOPS Version 4.0 dated 04/10/2018
A5333s LPC Version 4.0 dated 03/23/2018
These documents are on the A5333s PSWP

For future reference, all newsletters are available on the REPRIEVE Website.

We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at reprieve.news@fstrf.org

---

REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital

55 Fruit Street, 5LON 207

Boston, MA USA 02144

Our mailing address is:

reprieve.news@fstrf.org

Want to change how you receive these emails?

You can update your preferences or unsubscribe from this list.